Danicamtiv Enhances Systolic Function and Frank‐Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium
Main Authors: | Shi Shen, Lorenzo R. Sewanan, Daniel L. Jacoby, Stuart G. Campbell |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.121.020860 |
Similar Items
-
Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future
by: Shujing Zhou, et al.
Published: (2024-03-01) -
Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword
by: Jorik H. Amesz, et al.
Published: (2023-09-01) -
The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications
by: Arnold Péter Ráduly, et al.
Published: (2022-12-01) -
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care
by: Daniela Tomasoni, et al.
Published: (2022-06-01) -
Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis
by: Fadel Alqatati, et al.
Published: (2022-05-01)